CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.

Abstract

Background: Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.

Methods: Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS).

Results: The cut-off value of CXCL7 for PFS was 250 ng ml-1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml-1) had a significantly longer PFS (hazard ratio 0.323 (95% confidence interval 0.147-0.707), P=0.001). These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients.

Conclusions: CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / administration & dosage
  • Biomarkers, Tumor / blood
  • Carcinoma, Renal Cell / blood*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Carcinoma, Renal Cell / surgery
  • Disease-Free Survival
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Kidney Neoplasms / blood*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery
  • Killer Cells, Natural
  • Lymphocytes, Tumor-Infiltrating
  • Macrophages
  • Male
  • Mice
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Transplantation
  • Nephrectomy
  • Neutrophils
  • Prospective Studies
  • Pyrroles / therapeutic use*
  • Retrospective Studies
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Sunitinib
  • Survival Rate
  • beta-Thromboglobulin / metabolism*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Indoles
  • PPBP protein, human
  • Pyrroles
  • beta-Thromboglobulin
  • Bevacizumab
  • temsirolimus
  • Sunitinib
  • Sirolimus